Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria

NCT06873516 is registered in ClinicalTrials.gov with Evommune, Inc. as lead sponsor.

NCT NCT06873516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Lead sponsor
Evommune, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2025
Completion date
June 5, 2026
Enrollment
182 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria